title: Optimal use of maraviroc in clinical practice.
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
authors.forename: Anna María
authors.initials: AM
authors.lastname: Geretti
authors.forename: Carlo-Federico
authors.initials: CF
authors.lastname: Perno
authors.forename: Gerd
authors.initials: G
authors.lastname: Fätkenheuer
authors.forename: Deenan
authors.initials: D
authors.lastname: Pillay
authors.forename: Jacques
authors.initials: J
authors.lastname: Reynes
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tambussi
authors.forename: Vincent
authors.initials: V
authors.lastname: Calvez
authors.forename: José
authors.initials: J
authors.lastname: Alcamí
authors.forename: Juergen
authors.initials: J
authors.lastname: Rockstroh
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D065100:CCR5 Receptor Antagonists; D018791:CD4 Lymphocyte Count / Q000379:methods; D003510:Cyclohexanes / Q000008:administration & dosage*; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D005260:Female; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage*; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D008297:Male; D000077592:Maraviroc; D019713:Receptors, CCR5 / Q000302:isolation & purification*; D014230:Triazoles / Q000008:administration & dosage*; D018523:Tropism / Q000502:physiology; D019562:Viral Load
chemical_list: D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D019713:Receptors, CCR5; D014230:Triazoles; D000077592:Maraviroc